Article

Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.

2024-10-30

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>: Immune checkpoint inhibitors (ICI) are an essential systemic therapy for advanced melanoma. However, most melanomas develop resistance to ICI. Tumor-derived soluble PD-L1 (sPD-L1) and other soluble immunosuppressive factors drive checkpoint inhibitor resistance and correlate with inferior survival. We previously showed that therapeutic plasma exchange (TPE) re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f24569b3-cfed-5ae0-ad60-e41ef61dc9ed
DOI: 10.21203/rs.3.rs-4542220/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.DOI 10.21203/rs.3.rs-4542220/v1Read

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).Semantic proximity Read

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.Semantic proximity Read

Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanomaSemantic proximity Read

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read

Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity Read

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.Semantic proximity Read

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1Semantic proximity Read

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read